Urothelial neoplasm

Summary

Urothelial neoplasm (MONDO:0024337) is a cancer (an umbrella term covering 5 Mondo subtypes) and 7 clinical trials. Top therapeutic interventions include pembrolizumab. A subtype of urinary system neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Umbrella term: 5 Mondo subtypes
• Clinical trials: 7

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	urothelial neoplasm
Mondo ID	MONDO:0024337
NCIT	C39852
UMLS	C1519840
MedGen	275551
Anatomy (UBERON)	UBERON:0000365
Is cancer (heuristic)	yes

Also known as: neoplasm of urothelium · transitional cell neoplasm of the urinary tract · tumor of urothelium · tumour of urothelium · urothelial neoplasm · urothelium neoplasm · urothelium neoplasm (disease) · urothelium tumor · urothelium tumour

Disease family

This is a subtype of urinary system neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › urinary system neoplasm › urothelial neoplasm

Related subtypes (7): benign urinary system neoplasm, urinary bladder neoplasm, malignant urinary system neoplasm, prostate phyllodes tumor, ureter neoplasm, kidney neoplasm, urethra neoplasm

Subtypes (5): papillary urothelial neoplasm, urinary tract non-invasive transitional cell neoplasm, urothelial dysplasia, infiltrating urothelial carcinoma, urothelial carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 7.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE1/PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05845814	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
NCT04260802	PHASE1/PHASE2	TERMINATED	A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
NCT04200963	PHASE1	COMPLETED	A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
NCT03698721	Not specified	NOT_YET_RECRUITING	Urothelium Tissue Engineering Using Biopsies From Transurethral Resection of Prostate
NCT06026189	Not specified	RECRUITING	Safely Reduce Cystoscopic Evaluations for Hematuria Patients
NCT06863844	Not specified	RECRUITING	The Evaluation of Molecular Markers From PRedittivI DNA of Clinical Outcomes in Patients With UROthelial Tumor
NCT04770974	Not specified	UNKNOWN	Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic Characteristic

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PEMBROLIZUMAB	4	1